The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
@Mr Speculator. You might find this interesting.
https://www.finddx.org/eoi-covid19-ag-rdt/
For example. There's talk of One Direction reuniting for their 10th anniversary this year. How can they do that currently?
"One Direction will celebrate their 10th anniversary on July 23, 2020. For months, the group's members have been hinting at a reunion. Liam Payne has been the most outspoken about the anniversary and said that he's been in communication with the other band members."
Liam has already had experience with a VR gig and it sounds as though he's leading on the reunion. Okay, so it's probably short notice for them to do a streamed gig on 23rd July, but they could announce a gig on that date.
And even more so if social distancing measures are in place for extended length of time. Where do you go to monetise your act? Artists are all keeping their profile high on Insta and Youtube. But where's the money? I think agents will be lining them up to do exclusive gigs at Brixton.
So that's a good question, but rather than thinking about it from the point of what artists does the venue currently showcase, think of it as it as it will be the venue to go to, to get your act to the world. It's a draw to the artist.
RNS: Oracle Power PLC
("Oracle" or the "Company")
Exercise of Warrants by HH Sheikh Ahmed Bin Dalmook Juma Al Maktoum
& Issue of Equity
Oracle Power PLC (AIM:ORCP) announces that today it has received notices of exercise from the private office of His Highness Sheikh Ahmed Bin Dalmook Juma Al Maktoum ("HH Private Office") in respect of certain pre-existing warrants to subscribe for, in aggregate, 100,000,000 new ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares") at a price of 0.25 pence per share. The exercise of these warrants amounts to an aggregate cash subscription of £250,000.
Application will be made to the London Stock Exchange plc for the admission of the 100,000,000 new Ordinary Shares to trading on AIM ("Admission"). Admission is expected to become effective at 8.00 a.m. on 3 July 2020. On Admission HH Private Office will hold 300,000,000 Ordinary Shares of the shares in issue.
On Admission, the Company will have 1,977,913,151 Ordinary Shares in issue. The Company holds no shares in treasury. Accordingly, the figure of 1,977,913,151 can be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Naheed Memon, CEO of Oracle, said:
"The continued support that we receive from His Highness Sheikh Ahmed Bin Dalmook Juma Al Maktoum is gratefully received and I am delighted that he is increasing his exposure to Oracle Power as a long-term strategic investor. With the overall shareholding of HH Private Office increasing by 50%, I believe that today's exercise of warrants reinforces His Highness's confidence in the quality of our existing interests and our ability to deliver on our commercial milestones. This is also a testament to the trust he places in the management of the Company and the belief he has in Oracle's potential to grow into an international natural resource and power developer. The management is striving to expedite progress at Thar Block VI Project and achieve its stated commercial and operational objectives. The board appreciates the support of its strategic and investment partners and remains committed to delivering high returns for the benefit of all stakeholders."
From the horse (Alastair)'s mouth....
"So let’s take a look at where we are in our development of the saliva-based COVID-19 rapid antigen test. In mid May we provided our partner Cytiva with a number of affimer reagents against the virus spike protein and since then our colleagues at Cytiva have been preparing the various components of a rapid test strip. By the end of June, on schedule, we will have generated laboratory performance data for the first prototype devices."
Quick recap.
End of June.
Five. Trading. Days. Away.
@Monkshood. I'd love to say I followed what you said word for word. But I love that you sound like you know what you're talking about. Assuming, therefore, that you are invested here, and after all you have said, then that is good enough for me. insert smiley face emoji.
Don't stop though, I am sure there are more scientific learned members of this board who understood that perfectly.
Dougal. With respect, the same language was used with NCYT. Scared quite a few people out at 80p! As you no doubt know, we are in unprecedented times. There is a lot of more demand than supply for testing kits. The market is huge. Normal parameters do not apply.
Often happens with good news, SP goes up first thing, then starts to go down, people then either sell for their 10/20% or panic sell, then everyone else piles back in for a nice steady rise, leaving those that panic sold trying to get back in. Tends to lead to a lot of people talking the stock down to get their re-entry price.
I think this is a great share and I'm not remotely worried about mini ups and downs. See what your money looks like in a month to six weeks' time (I won't even mention the longer term). We still have a lot of news to come, and there may well be some volatility along the way but I will sleep better if I'm not trying to second guess intraday prices. I have my exit plan and I'm not ready to use it yet! :-)
Vaccine partnership:
http://www.ox.ac.uk/news/2020-04-30-landmark-partnership-announced-development-covid-19-vaccine
From the last RNS as a little reminder for you all.
Avacta owns the intellectual property relating to the SARS-COV-2 Affimer reagents and retains all commercial rights. Avacta is in active discussion with other global diagnostic companies to develop Affimer-based COVID-19 antigen tests to increase high-throughput testing capacity on a world-wide scale.
So....let's recap...
Owns the intellectual property
Retains all commercial rights
Active discussion
Global diagnostic companies
Increase high-throughput testing capacity
Worldwide scale
See you in the morning.
https://twitter.com/Tweet_trader01/status/1252858019991269378
I'm already in. Have been in since 19p. I have top sliced for the sake of transparency, but I think it's only fair to those who think that an order for 50 million tests is going to be announced tonight should have the facts.
By all means, buy ODX for Elisa tests, but the breakthrough reliable test of 50 million orders referred to in Daily Mail is not going to be announced any time soon. Please do listen to Dr Mario Gualano, CEO of BBI Solutions (part of the UK-RTC consortium) on the radio. He thinks the Mail were referring to the antigen they are using as a basis for the test as identified by Prof John Bell at Ox Uni which form part of the building blocks for the test. But the final product (rapid test for using at home) is up to 3 months away. Could still be an amazing opportunity, but don't expect any news relating to the Daily Mail story yesterday. They got the wrong end of the stick!
https://www.bbc.co.uk/sounds/play/m000hmm8
Listen from 2:22:00